Candriam Luxembourg S.C.A. cut its stake in Bluebird Bio Inc. (NASDAQ:BLUE) by 24.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,000 shares of the company’s stock after selling 14,500 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Bluebird Bio were worth $1,905,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BLUE. Seven Eight Capital LLC acquired a new position in Bluebird Bio during the first quarter valued at approximately $108,000. Legal & General Group Plc increased its position in Bluebird Bio by 31.6% in the first quarter. Legal & General Group Plc now owns 2,895 shares of the company’s stock valued at $123,000 after buying an additional 695 shares during the period. BlackRock Inc. increased its position in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the period. OMERS ADMINISTRATION Corp increased its position in Bluebird Bio by 1.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 6,000 shares of the company’s stock valued at $255,000 after buying an additional 100 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Bluebird Bio during the first quarter valued at approximately $370,000.
Bluebird Bio Inc. (NASDAQ:BLUE) traded up 0.21% during mid-day trading on Monday, hitting $67.92. 1,117,405 shares of the stock traded hands. Bluebird Bio Inc. has a 12 month low of $35.37 and a 12 month high of $99.70. The company’s 50 day moving average is $60.22 and its 200 day moving average is $49.44. The company’s market cap is $2.52 billion.
Bluebird Bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter in the prior year, the business posted ($1.57) EPS. The company’s revenue for the quarter was down 68.6% compared to the same quarter last year. On average, analysts expect that Bluebird Bio Inc. will post ($6.18) earnings per share for the current fiscal year.
Several research analysts recently commented on the stock. Jefferies Group reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Bluebird Bio in a report on Friday, September 23rd. Maxim Group set a $85.00 price target on shares of Bluebird Bio and gave the company a “buy” rating in a report on Thursday, September 22nd. Cowen and Company reissued an “outperform” rating on shares of Bluebird Bio in a report on Friday, September 9th. Vetr downgraded shares of Bluebird Bio from a “buy” rating to a “hold” rating and set a $44.44 price target for the company. in a report on Monday, July 4th. Finally, Wedbush reissued an “outperform” rating and issued a $117.00 price target on shares of Bluebird Bio in a report on Monday. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $90.25.
In other Bluebird Bio news, insider David Davidson sold 1,000 shares of the stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $45.08, for a total value of $45,080.00. Following the transaction, the insider now directly owns 10,600 shares in the company, valued at $477,848. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Sullivan sold 2,912 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total transaction of $160,189.12. Following the completion of the transaction, the insider now owns 4,456 shares in the company, valued at $245,124.56. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by company insiders.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bluebird Bio Inc. (NASDAQ:BLUE).
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.